Kuwait Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Kuwait Pharmaceuticals & Healthcare Report

The Kuwait Pharmaceuticals and Healthcare Report

Independent 5-year pharmaceutical and healthcare industry forecasts for Kuwait.

Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Kuwaiti pharmaceutical and healthcare industry.

Competitive intelligence, Kuwaiti pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Kuwaiti market.

The Kuwait Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Kuwait Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Kuwaiti pharmaceutical and healthcare industry.

Key Benefits of Report

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Kuwait Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Table of Contents

Chapter - Executive Summary

Kuwait Pharmaceuticals And Healthcare Industry SWOT
Kuwait Political SWOT
Kuwait Economic SWOT
Kuwait Business Environment SWOT

Chapter - Pharmaceutical Business Environment Ratings

Table: Regional Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns

Chapter - Kuwait – Market Summary

Regulatory Regime
Foreign Direct Investment Regulations
Intellectual Property Regime
IP Shortcomings
Pricing And Reimbursement Regime
Public Procurement Of Medicines
Regional Harmonisation
Free Trade Agreements

Chapter - Industry Developments

Epidemiology
Healthcare Sector
Primary Care
Secondary Care
Recent Public Health Developments
Healthcare Insurance
Healthcare Reforms
Regional Developments
International Collaboration
Pharmaceutical Sector
Research And Development
Biotechnology Sector
Medical Devices
Table: Diverse Potential For Product Launches: New Products For 2009

Chapter - Industry Forecast Scenario

Overall Market Forecasts
Table: Kuwait – Drug Expenditure Indicators, Historical Data and Forecasts
Key Growth Factors – Industry
Table: Kuwait – Health Expenditure Indicators, Historical Data and Forecasts
Key Growth Factors – Macroeconomic
Table: Kuwait – Economic Activity, 2006-2013
Prescription Drug Market Forecast
Table: Kuwait - Prescription Market Indicators, Historical Data And Forecasts (KWDmn unless otherwise stated)
Patented Drug Market Forecast
Table: Kuwait – Patented Market Indicators, Historical Data And Forecasts
Generics Market Forecast
Table: Kuwait – Generics Market Indicators, Historical Data And Forecasts
OTC Market Forecast
Table: Kuwait – OTC Market Indicators, Historical Data And Forecasts (KWDmn unless otherwise stated)
Export/Import Market Forecasts
Table: Kuwait – Pharmaceutical Trade Indicators, Historical Data And Forecasts (US$mn unless otherwise stated)
Table: India's Export Of Pharmaceutical Products To GCC Countries (US$mn)
Medical Devices Forecast
Table: Kuwait's Medical Devices Market, 2003-2013 (US$mn unless otherwise stated)
Other Healthcare Data
Table: Kuwait – Other Healthcare Indicators, Historical Data And Forecasts, 2003-2013
Key Risks To BMI Forecasts

Chapter - Competitive Landscape

Company Profiles
Multinationals
Novartis
Sanofi-Aventis
Pfizer
GlaxoSmithKline
Merck & Co
Johnson & Johnson
Indigenous Players
Advanced Technology Company
Bader Sultan & Bros
Safwan Trading And Contracting Company

Chapter - Country Snapshot: Kuwait Demographic Data

Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 1997-2006
Table: Consumer Expenditure, 2000-2012

Chapter - BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Kuwait Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Executive Summary

The Kuwaiti pharmaceutical market – now slipping to fifth place from third out of the 17 regional markets surveyed in the Middle East and Africa (MEA) Business Environment Ranking matrix - will record unspectacular growth in the next five years. The rate of this growth will also be offset by inflation and the government’s cost-containment policy, focusing on generic reimbursement. Overall, the market is likely to reach around US$508mn at consumer prices by 2013, up from US$377mn in 2008, equal to US$131 per capita, with both figures small in global terms. The market will post a compound annual growth rate (CAGR) of 5.38% in nominal terms, or a slightly higher 6.15% in US dollar terms, While prescription medicines will continue to dominate a lion’s share of the overall market, the recent regionwide regulatory changes – notably the recent attempts to draft legislation on alternative and traditional medicines - will stimulate the development of the over-the-counter (OTC) segment, although it will still remain small in absolute term.

Other segments of the healthcare market are also severely limited by the small size of Kuwait's population. Nevertheless, BMI expects the medical device sector to grow over the coming years, supported by government's strategy to continue undertaking reforms in the healthcare sector as well as partially by the efforts of Kuwaiti distributers seeking new suppliers. We estimated that the market was worth US$78.7mn in 2008, with the figure forecast to top US$98.1mn in 2013, growing at a CAGR of some 3.74% in nominal terms. Given that imports meet virtually all of the demand, foreign companies and their local distributors will be the beneficiaries of this trend. The recent purchase by the Kuwaiti government of nuclear radiation protection drugs, amid concerns of a fallout of a possible conflict between Israel/the US and Iran, or a meltdown of the soon-to-be-operational Iranian Bushehr nuclear power plant, may also lead to purchases of radiation detection and similar medical devices.

In the meantime, the Kuwaiti government is under increasing pressure to deal with the economic turmoil, and, as parliament becomes even angrier with the government, this could lead the latter to make some potentially damaging decisions. There is also a risk of early elections: new polls are not due until 2012, but Kuwait has a history of dissolving governments. While we would not expect this to result in any meaningful change of government - parliament is already dominated by the opposition and the royal family is not about to be overthrown - it could destabilise the country, delay reforms, deter investors and lead to even further fiscal laxity. Nevertheless, although Kuwait faces substantial structural challenges over the long-term, the energy sector will continue to grow in real terms to 2018, keeping the government in surplus.

Kuwait Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Read about our other Pharmaceuticals & Healthcare Reports

Africa

Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe

Asia

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam

Caribbean

Puerto Rico

Europe

Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan

Latin America

Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela

Middle East

Bahrain, Iran, Israel, Jordan, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates

North America

Canada and United States
Business Monitor International Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 25 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.